Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Sound Maturing: Wellbeing Tips for Each Life Stage - 2Horror and fear in West Bank as Israel approves hanging Palestinians convicted of murdering Israelis
- 3Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- 4The most effective method to Promoter for Cutthroat Medical attendant Compensations in Your Medical services Office
- 5NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- April's full moon decides the date of Easter — here's how it works
- Undeniably popular Historical centers: Where Craftsmanship and History Meet
- Israel says soldiers wounded in Gaza fighting amid fragile truce
- Remain Cool and Solid: Top Summer Food sources for 2024
- Easy to understand Tech: Cell phones for Old in 2024
- Exemplary Fragrances: A Manual for Notorious Scents
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- Pick Your Favored method of transportation
- Building a Flourishing Business: Illustrations from Business people
